Circassia Group saw £15.5m in revenue growth in the first half of 2022, which is an 11 per cent bump compared to the same period in 2021. Peel Hunt says the medical device firm's impressive results are due to a "very successful pivot of the business", after it changed to a "distributor-led sales model" and slashed overhead costs. Circassia retains its Hold rating, with a 40p target price.

Trustpilot expects to bring in $73m (£61m) of revenues for the first half of 2022, which is an 18 per cent boost from 2021. Peel Hunt says the business review website has not been hit by "the impact of a weakening macro environment", but that a "slowdown in bookings" could alter this. The analyst maintains its Buy rating for Trustpilot, with a 98p target price.

(c) 2022 City A.M., source Newspaper